Rocket Pharmaceuticals (RCKT) Convertible Debt (2015 - 2021)

Rocket Pharmaceuticals has disclosed Convertible Debt across 7 years of filings, most recently posting $35.5 million for Q1 2021.

• Convertible Debt for Q1 2021 came in at $35.5 million, down 22.38% year-over-year; the trailing twelve-month figure through Mar 2021 was $35.5 million (down 22.38% YoY), and the FY2020 annual result was $35.1 million, down 22.16% from the prior year.
• Convertible Debt came in at $35.5 million for Q1 2021 at Rocket Pharmaceuticals, up from $35.1 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $49.4 million in Q3 2017 to a low of $35.1 million in Q4 2020.
• The 5-year median for Convertible Debt is $42.7 million (2019), against an average of $43.0 million.
• Across the five-year window, Convertible Debt advanced 8.69% in 2019 and retreated 22.38% in 2021, its largest moves.
• Rocket Pharmaceuticals' Convertible Debt stood at $49.4 million in 2017, then dropped by 16.08% to $41.4 million in 2018, then advanced by 8.69% to $45.0 million in 2019, then dropped by 22.16% to $35.1 million in 2020, then rose by 1.36% to $35.5 million in 2021.
• The last three Convertible Debt figures came in at $35.5 million (Q1 2021), $35.1 million (Q4 2020), and $42.1 million (Q3 2020), per Business Quant data.